• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Inspira Technologies Oxy B.H.N. Ltd.

    9/10/25 4:38:16 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care
    Get the next $IINN alert in real time by email
    S-8 1 ea0254938-s8_inspira.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on September 10, 2025

    Registration No. 333 -           

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    (Exact name of registrant as specified in its charter)

     

    State of Israel   Not applicable
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    2 Ha-Tidhar St., Ra’anana, 4366504 Israel

    (Address of Principal Executive Offices)

     

    Inspira Technologies OXY B.H.N. LTD.

    Amended and Restated 2019 Equity Incentive Plan

    (Full title of the plan)

     

    Puglisi & Associates

    850 Library Ave., Suite 204, Newark, DE 19711

    Tel: (302) 738-6680

    (Name, Address and Telephone Number of Agent for Service)

     

    COPIES TO:

     

    Oded Har-Even, Esq.

    Ron Ben-Bassat, Esq.

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, NY 10020

    Tel: (212)-660-3000

    Adv. Reut Alfiah

    Adv. Gal Cohen

    Sullivan & Worcester Tel-Aviv (Har-Even & Co.)

    28 HaArba’a St. HaArba’a Towers

    North Tower, 35th floor

    Tel-Aviv, Israel 6473925

    Tel: +972 74-758-0480

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☐
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On August 5, 2021, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant or the Company, filed a Registration Statement on Form S-8 (File No. 333-259057), or the Original Registration Statement, with the Securities and Exchange Commission, or the SEC, to register an aggregate of 4,180,898 ordinary shares, no par value per share, of the Company, or the Ordinary Shares, that may be issued pursuant to the Company’s 2019 Equity Incentive Plan, or the 2019 Plan. On March 15, 2024, the Company filed an additional Registration Statement on Form S-8 (File No. 333-277980) with the SEC to register an additional 2,997,671 Ordinary Shares that may be issued pursuant to the 2019 Plan. On March 5, 2025, the Company filed an additional Registration Statement on Form S-8 (File No. 333-285565) with the SEC to register an additional 3,000,000 Ordinary Shares that may be issued pursuant to the 2019 Plan.

     

    The 2019 Plan was originally adopted by the board of directors of the Company in November 2019, amended in September 2021, and further amended and restated in March 2025, or the Amended and Restated 2019 Plan.

     

    The Company is filing this Registration Statement on Form S-8, or this Registration Statement, to register an additional 1,184,910 Ordinary Shares reserved for issuance in connection with securities awards which may hereafter be granted under the Amended and Restated 2019 Plan.

     

    Pursuant to General Instruction E to Form S-8, the contents of the Original Registration Statement are incorporated herein by reference, except for Items 3 and 8 of Part II of the Original Registration Statement, which are being updated by this Registration Statement.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the Plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended, or the Securities Act.

     

    1

     

     

    PART II

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The following documents filed by the Company with the SEC are incorporated by reference into this Registration Statement:

     

      ● Our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on March 10, 2025 and as amended on March 28, 2025;

     

      ● Our Reports on Form 6-K furnished on March 11, 2025 (with respect to the first paragraph, the sections titled “Recent Business and Operational Highlights,” “Full Year 2024 Financial Results” and “Forward-Looking Statements” of the press release attached therewith as Exhibit 99.1), March 13, 2025, March 14, 2025, March 14, 2025, March 25, 2025 (with respect to the first, second, fourth, and fifth paragraphs and the section titled “Forward-Looking Statements”), April 7, 2025 (with respect to the first, second, and fifth paragraphs and the section titled “Forward-Looking Statements”), April 10, 2025, April 15, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”), April 23, 2025 (with respect to the first three and fifth paragraphs and the section titled “Forward-Looking Statements”), May 7, 2025 (with respect to the first three and fifth paragraphs and the section titled “Forward-Looking Statements”), May 12, 2025, May 27, 2025 (with respect to the first, second, fifth and sixth paragraphs and the section titled “Forward-Looking Statements”), May 29, 2025 (with respect to the first, second, fourth, fifth and sixth paragraphs and the section titled “Forward-Looking Statements”), May 30, 2025, June 5, 2025 (with respect to the first, second, fourth and fifth paragraphs and the section titled “Forward-Looking Statements”), June 11, 2025, June 23, 2025, July 1, 2025, July 2, 2025 (with respect to the first, second, and fifth paragraphs and the section titled “Forward-Looking Statements”), July 7, 2025 (with respect to the first three paragraphs and the section titled “Forward-Looking Statements”), July 10, 2025 (with respect to the first two paragraphs and the section titled “Forward-Looking Statements”), July 17, 2025, July 18, 2025 (with respect to the first two paragraphs and the section titled “Forward-Looking Statements”), July 31, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”); August 19, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”), August 22, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”) and September 2, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”); and

     

      ● The description of our securities contained in Exhibit 2.1 to our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on March 10, 2025, and as amended on March 28, 2025.

     

    II-1

     

     

    In addition to the foregoing, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act and all reports on Form 6-K subsequently filed by the Registrant which state that they are incorporated by reference herein, prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8.   Exhibits.
    4.1   Amended and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (incorporated by reference to Exhibit 99.1 to the Company’s Report on Form 6-K (File No. 001-40303) filed on December 20, 2021).
         
    5.1*   Opinion of Sullivan & Worcester Tel Aviv (Har-Even & Co.)
         
    23.1*   Consent of Ziv Haft, member firm of BDO, independent registered public accounting firm.
         
    23.2*   Consent of Sullivan & Worcester Tel Aviv (Har-Even & Co.) (included in the opinion filed as Exhibit 5.1 to this Registration Statement)
         
    24.1*   Power of Attorney (included on signature page)
         
    99.1   Amended and Restated Inspira Technologies Oxy B.H.N. Ltd. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Form S-8 (File No. 333-285565) filed on March 5, 2025).
         
    107*   Filing Fee Table.

     

    *Filed herewith.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in Ra’anana, Israel, on September 10, 2025.

     

      INSPIRA TECHNOLOGIES OXY B.H.N. LTD.
         
      By: /s/ Dagi Ben-Noon
        Name:   Dagi Ben-Noon
        Title: Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    We, the undersigned officers and directors of Inspira Technologies Oxy B.H.N. Ltd., hereby severally constitute and appoint Dagi Ben-Noon and Yafit Tehila, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this Registration Statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming our signatures to said amendments to this Registration Statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature    Title    Date 
             
    /s/ Dagi Ben-Noon   Chief Executive Officer and Director     September 10, 2025
    Dagi Ben-Noon    (Principal Executive Officer)     
             
    /s/ Yafit Tehila   Chief Financial Officer    September 10, 2025
    Yafit Tehila    (Principal Financial and Accounting Officer)     
             
    /s/ Tal Parnes   Chairman of the Board of Directors    September 10, 2025
    Tal Parnes         
             
    /s/ Lior Amit   Director    September 10, 2025
    Lior Amit         
             
    /s/ Limor Rozen   Director    September 10, 2025

    Limor Rozen  

           

     

    II-3

     

      

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act, the undersigned, Puglisi & Associates, the duly authorized representative in the United States of Inspira Technologies Oxy B.H.N. Ltd., has signed this Registration Statement on Form S-8 on September 10, 2025.

     

      Puglisi & Associates
       
      Authorized U.S. Representative
       
      /s/ Donald J. Puglisi
      Name:  Donald J. Puglisi
      Title: Managing Director

     

     

    II-4

     

     

     

     

    Get the next $IINN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IINN

    DatePrice TargetRatingAnalyst
    11/1/2021$9.00 → $10.00Buy
    Aegis Capital
    8/26/2021$9.00Buy
    Aegis Capital
    More analyst ratings

    $IINN
    SEC Filings

    View All

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    10/1/25 8:00:39 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    9/18/25 8:00:09 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Inspira Technologies Oxy B.H.N. Ltd.

    424B5 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    9/16/25 5:00:17 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

    RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio

    10/1/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed

    RA'ANANA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it will present its HYLA blood sensor ("HYLA") to the global medical community for the first time. The presentation will take place at the U.S. ELSO Annual Conference in Washington, D.C., between September 27–30, 2025. This official unveiling follows the Company's recent announcement of the HYLA sensor's performance data, which demonstrated 97.35% accuracy compared to standard blood gas analyzers. The ELSO conference, widely regarded as the largest an

    9/18/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance

    RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal results for its HYLA blood sensor, achieving 97.35% accuracy in its latest performance testing phase that will support its upcoming U.S. Food and Drug Administration ("FDA") submission. These results represent a significant advancement from the initial data obtained in a clinical study, as announced on March 4, 2025. The clinical study from March, conducted at a medical center ranked among the world's leading hospitals, provided validation fo

    9/11/25 9:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously

    11/1/21 12:39:26 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Aegis Capital initiated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00

    8/26/21 10:05:11 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    11/14/24 4:08:42 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/14/24 3:40:01 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd. (Amendment)

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/12/24 4:05:09 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Financials

    Live finance-specific insights

    View All

    Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

    RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio

    10/1/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates

    Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an

    3/11/25 8:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira™ Announces Business Plan Targets

    Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today.     On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's

    6/20/24 9:25:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Leadership Updates

    Live Leadership Updates

    View All

    PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon

    Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn

    2/6/25 8:27:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors

    RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.     Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision. As a serial entrepreneur, Parnes has demonstrated

    1/21/25 8:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

    RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the

    12/11/23 9:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care